Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.59 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.59 |
| ▸ | HTR6 | P50406 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3556522 | 0.94 | SLC16A3 (0.58) | MEN1KMT2ASLC16A3HDAC1HDAC8 | |
| SCHEMBL3553555 | 0.91 | HTR6 (0.67) | MEN1KMT2ASLC16A3AKR1C3HTR6 | |
| SCHEMBL3555334 | 0.90 | KAT6A (0.56) | MEN1KMT2ASLC16A3POLB | |
| SCHEMBL3555180 | 0.90 | ALDH1A1 (0.57) | MEN1KMT2ASLC16A3HDAC1HDAC8 | |
| SCHEMBL3554962 | 0.90 | ALDH1A1 (0.64) | MEN1KMT2ASLC16A3AKR1C3POLB | |
| SCHEMBL3557363 | 0.90 | PRMT1 (0.59) | MEN1KMT2ASLC16A3AKR1C3POLB | |
| SCHEMBL3562814 | 0.90 | SLC16A3 (0.71) | MEN1KMT2ASLC16A3POLB | |
| SCHEMBL3554909 | 0.89 | CA12 (0.60) | MEN1KMT2ASLC16A3POLB | |
| SCHEMBL3561276 | 0.89 | AKR1C3 (0.63) | MEN1KMT2ASLC16A3HDAC1HDAC8 | |
| SCHEMBL3556207 | 0.89 | MEN1 (0.57) | MEN1KMT2ASLC16A3HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | claimed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | MEN1 2548/4885KMT2A 4045/4885SLC16A3 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.